Sibeprenlimab in IgA Nephropathy — Interim Analysis of a Phase 3 Trial

Vlado Perkovic

University of New South Wales, Sydney

Hernán Trimarchi

Hospital Británico, Buenos Aires

Vladimir Tesař

First Faculty of Medicine and General University Hospital, Charles University, Prague, Czech Republic

Richard Lafayette

Muh Geot Wong

Concord Repatriation General Hospital, Concord, NSW, Australia

Jonathan Barratt

Yusuke Suzuki

Adrian Liew

Mount Elizabeth Novena Hospital, Singapore

Hong Zhang

Kevin Carroll

KJC Statistics, Cheadle, United Kingdom

Vivekanand Jha

George Institute for Global Health, UNSW, New Delhi, India

Alejandra Quevedo

Investigación Clinica Aplicada SRL, Buenos Aires

Seung Hyeok Han

Yonsei University College of Medicine, Seoul, South Korea

Manuel Praga

Department of Medicine, Complutense University, Madrid

Bobby Chacko

Nephrology and Transplantation, John Hunter Hospital and University of Newcastle, Newcastle, NSW, Australia

Manisha Sahay

Osmania General Hospital, Hyderabad, India

Chee Kay Cheung

University of Leicester, Leicester, United Kingdom

Laura Kooienga

Colorado Kidney Care, Denver

Michael Walsh

Department of Medicine, McMaster University, Hamilton, ON, Canada

Jing Xia

Chinese Academy of Sciences , , ,

Cecile Fajardo

Otsuka Pharmaceutical Development and Commercialization, Princeton, NJ

Lokesh Shah

Otsuka Pharmaceutical Development and Commercialization, Princeton, NJ

Jeffrey Hafkin

Otsuka Pharmaceutical Development and Commercialization, Princeton, NJ

Dana V. Rizk

University of Alabama at Birmingham, Birmingham